BRISBANE, Calif. and ST. LOUIS, Dec. 06, 2020 (GLOBE NEWSWIRE) -- Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced the presentation of new preclinical data on AO-176 at the ASH Annual Meeting 2020. AO-176 is an anti-CD47 antibody with a potential best-in-class profile that works by blocking the “don’t eat me” signal and also by directly killing tumor cells, with preferential binding to tumor versus normal cells. Currently, AO-176 is being evaluated in Phase 1/2 clinical trials for the treatment of patients with select solid tumors and multiple myeloma, both as monotherapy and in combination with standard therapies.

Read this article:
Arch Oncology Presents New Preclinical Data on Highly Differentiated Anti-CD47 Antibody AO-176 at ASH 2020